Welcome to our dedicated page for Deciphera Pharma news (Ticker: DCPH), a resource for investors and traders seeking the latest updates and insights on Deciphera Pharma stock.
Deciphera Pharmaceuticals (DCPH) is a biotechnology innovator advancing targeted therapies for cancer through its expertise in kinase inhibition. This page provides investors and industry professionals with verified updates on the company's clinical developments, regulatory milestones, and strategic initiatives.
Access real-time announcements including quarterly earnings reports, FDA filings, clinical trial data, and partnership agreements. Our curated collection ensures you stay informed about DCPH's progress in developing small molecule therapeutics, particularly following its integration with Ono Pharmaceutical's global oncology network.
Key updates cover research breakthroughs, pipeline advancements, and operational developments within the company's Boston and Kansas research hubs. Bookmark this page for direct access to primary source materials and objective analysis of Deciphera's position in the competitive oncology therapeutics landscape.
Deciphera Pharmaceuticals (NASDAQ: DCPH) plans to initiate the pivotal Phase 3 INSIGHT study of QINLOCK versus sunitinib for second-line GIST patients with specific KIT mutations in late 2023. The company also expects to complete enrollment in the Phase 3 MOTION study of vimseltinib in the first half of 2023, announcing results later in the year. Preliminary unaudited revenue for Q4 2022 is estimated at $36 million, with a total of $134 million for the year. As of December 31, 2022, the company reported approximately $339 million in cash and equivalents, positioning it to fund operations through 2025.
Deciphera Pharmaceuticals (DCPH) announced positive results from an exploratory analysis of QINLOCK in the INTRIGUE Phase 3 study, notably for patients with specific KIT mutations. Key findings include a median progression-free survival (PFS) of 14.2 months for QINLOCK, compared to 1.5 months for sunitinib, with a hazard ratio of 0.22. The objective response rate was 44.4% for QINLOCK versus 0% for sunitinib. The company plans to initiate a pivotal Phase 3 clinical study, known as INSIGHT, in the second half of 2023.
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) has announced that CEO Steve Hoerter will present at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023, at 9:45 AM PT. A live webcast of the presentation will be accessible via the company’s website, with a replay available for 30 days afterward. Deciphera focuses on developing innovative cancer treatments, utilizing its proprietary switch-control kinase inhibitor platform. The company's QINLOCK® is already approved in several markets, including the United States and Europe.
Deciphera Pharmaceuticals (NASDAQ: DCPH) will have its CEO, Steve Hoerter, participate in a virtual fireside chat at the JMP Securities Hematology and Oncology Summit on December 6, 2022, at 10:40 AM ET. A live webcast can be accessed on the Company’s website under the 'Events and Presentations' section, with a replay available for 90 days post-event. Deciphera focuses on innovative cancer treatments and is advancing its proprietary switch-control kinase inhibitor platform, including the approved product QINLOCK® for fourth-line GIST treatment.
Deciphera Pharmaceuticals will participate in multiple investor conferences in November 2022. Key dates include:
- Stifel Healthcare Conference on November 15 at 10:55 AM ET in New York, NY
- Jefferies London Healthcare Conference on November 17 at 8:30 AM ET in London
- Piper Sandler 34th Annual Healthcare Conference on November 29 at 4:00 PM ET in New York, NY
Live webcasts will be accessible via the company’s investor website, with replays available for 90 days.
Deciphera is focused on developing innovative cancer therapies, including QINLOCK®, approved in multiple countries.
Deciphera Pharmaceuticals (DCPH) reported a third quarter 2022 total revenue of $36.0 million, a significant increase from $23.2 million in Q3 2021. The net product revenue for QINLOCK® rose 49% to $32.3 million. The company presented promising results for vimseltinib and DCC-3116 at the ESMO Congress 2022, showcasing their potential in treating cancer. DCPH reported a net loss of $43.0 million or $0.55 per share, an improvement from last year's $79.8 million loss. The company maintains a strong cash position of $371.6 million to fund operations into 2025.
Deciphera Pharmaceuticals (NASDAQ: DCPH) announced it will report its third quarter 2022 financial results on November 3, 2022, at 8:00 AM ET. A live conference call will follow, providing insights into the financial results and corporate updates. The earnings announcement is anticipated to shed light on Deciphera's performance, especially regarding its innovative cancer therapies using their proprietary switch-control kinase inhibitor platform. QINLOCK®, their treatment for fourth-line GIST, is already approved in multiple regions, including the US and EU.
Deciphera Pharmaceuticals (NASDAQ: DCPH) announced updated results for vimseltinib, a treatment for patients with tenosynovial giant cell tumor (TGCT), showing an objective response rate of 69% in Phase 1 and 53% to 46% in Phase 2 cohorts. The clinical benefit rate was 100%. Preliminary patient-reported outcomes indicated significant improvements in pain and stiffness. The ongoing Phase 3 MOTION study supports further investigation of vimseltinib, with a virtual investor event scheduled for September 11.
Deciphera Pharmaceuticals announced promising data from the Phase 1 study of its drug DCC-3116, a selective ULK1/2 inhibitor, targeting advanced cancers with RAS or RAF mutations. The drug was well-tolerated, with no serious adverse events, and demonstrated significant pharmacokinetic effects linked to anti-tumor efficacy. Dose escalation cohorts with MEK and KRASG12C inhibitors are expected to begin in Q4 2022. Initial results showed that 29% of patients achieved disease control at week 16.
Deciphera Pharmaceuticals (NASDAQ: DCPH) will host a virtual investor event on September 11, 2022, from 7:30 AM to 9:30 AM ET. The event will showcase clinical data from its DCC-3116 and vimseltinib programs, coinciding with the ESMO Congress 2022. Key opinion leaders Anthony W. Tolcher, M.D., and Jean-Yves Blay, M.D., Ph.D., will present findings. Attendees can register here. The presentations include DCC-3116 monotherapy results and vimseltinib's efficacy in treating tenosynovial giant cell tumors.
FAQ
What is the current stock price of Deciphera Pharma (DCPH)?
What is the market cap of Deciphera Pharma (DCPH)?
